MedTrace Logo

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

NCT04414852 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-06-04

No results posted yet for this study

Summary

The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.

Conditions

  • Subjects With Impaired Renal Function and Healthy Subjects

Interventions

DRUG

Apatinib Mesylate

All the subjects will be administrated with 250mg apatinib on day 1

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-05
Primary Completion
2021-01-15
Completion
2021-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414852 on ClinicalTrials.gov